mesna ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1711 3375-50-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • mesna
  • mercaptoethanesulfonic acid
  • reduced coenzyme M
A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE.
  • Molecular weight: 142.19
  • Formula: C2H6O3S2
  • CLOGP: -1.55
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 54.37
  • ALOGS: -1.05
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1.20 g Inhal.solution

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 28.13 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 62 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.65 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 20.50 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.36 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 30, 1988 FDA BAXTER HLTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 685.65 24.11 331 8461 118118 63362112
Encephalopathy 407.63 24.11 165 8627 38455 63441775
Mucosal inflammation 254.87 24.11 126 8666 46802 63433428
Pancytopenia 209.70 24.11 143 8649 96790 63383440
Neutropenia 204.54 24.11 179 8613 174826 63305404
Pyrexia 145.19 24.11 244 8548 470234 63009996
Cystitis haemorrhagic 109.69 24.11 35 8757 4088 63476142
Thrombocytopenia 105.80 24.11 117 8675 151040 63329190
Neurotoxicity 102.25 24.11 49 8743 16941 63463289
Leukopenia 93.92 24.11 81 8711 77209 63403021
Febrile bone marrow aplasia 86.49 24.11 34 8758 7291 63472939
Haematotoxicity 75.12 24.11 33 8759 9343 63470887
Toxic encephalopathy 72.31 24.11 29 8763 6550 63473680
Product use in unapproved indication 71.70 24.11 105 8687 178975 63301255
Cytomegalovirus infection 70.57 24.11 41 8751 20911 63459319
Aplastic anaemia 64.96 24.11 30 8762 9539 63470691
T-cell lymphoma refractory 53.05 24.11 9 8783 57 63480173
Anaemia 52.04 24.11 121 8671 293309 63186921
Sepsis 51.69 24.11 83 8709 153040 63327190
Venoocclusive liver disease 48.63 24.11 20 8772 4815 63475415
Cytokine release syndrome 48.17 24.11 28 8764 14286 63465944
Arthralgia 46.49 24.11 11 8781 569699 62910531
Hypokalaemia 44.60 24.11 63 8729 103741 63376489
Idiopathic pneumonia syndrome 43.07 24.11 10 8782 350 63479880
Bone marrow failure 42.40 24.11 34 8758 29256 63450974
Drug ineffective 37.93 24.11 54 8738 1044711 62435519
Vena cava thrombosis 36.19 24.11 13 8779 2174 63478056
Pneumothorax 35.07 24.11 24 8768 16237 63463993
Polyneuropathy 34.99 24.11 23 8769 14566 63465664
Platelet count decreased 33.88 24.11 59 8733 116063 63364167
BK polyomavirus test positive 33.31 24.11 6 8786 56 63480174
Myelosuppression 33.21 24.11 27 8765 23676 63456554
Amniotic fluid index decreased 32.75 24.11 5 8787 14 63480216
Chronic hepatitis B 32.75 24.11 8 8784 349 63479881
Pain 32.42 24.11 33 8759 740595 62739635
Mitral valve disease 31.00 24.11 12 8780 2468 63477762
Disease progression 30.28 24.11 58 8734 122700 63357530
Cardiotoxicity 29.70 24.11 17 8775 8421 63471809
Drug intolerance 29.35 24.11 4 8788 308657 63171573
Peripheral sensory neuropathy 28.91 24.11 16 8776 7435 63472795
Multiple organ dysfunction syndrome 28.23 24.11 37 8755 56715 63423515
Off label use 28.03 24.11 174 8618 674288 62805942
Hyperuricaemia 27.85 24.11 14 8778 5356 63474874
Periorbital cellulitis 27.26 24.11 8 8784 705 63479525
Blood phosphorus decreased 27.26 24.11 13 8779 4440 63475790
Posterior reversible encephalopathy syndrome 26.96 24.11 21 8771 17324 63462906
Peripheral swelling 26.37 24.11 3 8789 265939 63214291
Ejection fraction decreased 26.27 24.11 23 8769 22309 63457921
Hepatocellular injury 25.97 24.11 25 8767 27356 63452874
Depersonalisation/derealisation disorder 25.92 24.11 9 8783 1363 63478867
Candida sepsis 25.87 24.11 9 8783 1371 63478859
Hepatitis E 25.47 24.11 9 8783 1435 63478795
Candida test positive 25.46 24.11 8 8784 888 63479342
Mental status changes 24.82 24.11 29 8763 39570 63440660
Aplasia 24.75 24.11 12 8780 4247 63475983

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 682.42 21.70 452 10012 136397 34810070
Encephalopathy 286.35 21.70 160 10304 35159 34911308
Cystitis haemorrhagic 152.13 21.70 59 10405 5620 34940847
Pyrexia 142.40 21.70 309 10155 332704 34613763
Neutropenia 129.30 21.70 194 10270 156584 34789883
Mucosal inflammation 123.38 21.70 98 10366 38524 34907943
Venoocclusive liver disease 107.70 21.70 51 10413 7915 34938552
Cytokine release syndrome 90.55 21.70 66 10398 22811 34923656
Aplastic anaemia 89.58 21.70 48 10416 9668 34936799
Pancytopenia 80.02 21.70 119 10345 95038 34851429
Febrile bone marrow aplasia 74.12 21.70 40 10424 8169 34938298
Aplasia 70.17 21.70 32 10432 4556 34941911
SARS-CoV-2 test negative 63.97 21.70 20 10444 1000 34945467
Anal inflammation 63.16 21.70 21 10443 1279 34945188
Thrombocytopenia 62.91 21.70 142 10322 156105 34790362
Venoocclusive disease 60.18 21.70 25 10439 2842 34943625
Myelosuppression 59.57 21.70 48 10416 19217 34927250
Leukopenia 59.20 21.70 83 10381 62773 34883694
Proctalgia 57.64 21.70 30 10434 5693 34940774
Fanconi syndrome 57.41 21.70 21 10443 1699 34944768
Haematotoxicity 55.27 21.70 33 10431 8161 34938306
Neutrophil count decreased 53.43 21.70 71 10393 51033 34895434
Stomatitis 47.44 21.70 61 10403 42453 34904014
Accident 46.69 21.70 25 10439 5022 34941445
Acute graft versus host disease 45.98 21.70 27 10437 6476 34939991
Neurotoxicity 45.61 21.70 40 10424 17970 34928497
Foetal growth restriction 45.57 21.70 23 10441 4094 34942373
Platelet transfusion 44.95 21.70 17 10447 1509 34944958
Oesophagitis 36.72 21.70 31 10433 13230 34933237
Fall 36.65 21.70 8 10456 202877 34743590
Haemorrhoids 34.18 21.70 31 10433 14544 34931923
Death 33.64 21.70 42 10422 398007 34548460
Angiodysplasia 32.72 21.70 11 10453 693 34945774
Bone marrow failure 32.66 21.70 42 10422 29211 34917256
Fusarium infection 30.87 21.70 12 10452 1148 34945319
Chronic graft versus host disease 30.50 21.70 18 10446 4355 34942112
Septic shock 28.50 21.70 65 10399 71769 34874698
Polyneuropathy 26.11 21.70 27 10437 14869 34931598
Vomiting 25.99 21.70 144 10320 247477 34698990
Myocardial infarction 25.82 21.70 3 10461 121082 34825385
Engraftment syndrome 25.42 21.70 10 10454 987 34945480
Malassezia infection 25.19 21.70 5 10459 35 34946432
Drug therapeutic incompatibility 24.65 21.70 6 10458 116 34946351
Body temperature increased 24.37 21.70 28 10436 17340 34929127
Herpes zoster reactivation 23.52 21.70 7 10457 296 34946171
Agranulocytosis 23.20 21.70 32 10432 23789 34922678
Acute graft versus host disease in skin 22.85 21.70 16 10448 5185 34941282
Toxic encephalopathy 22.71 21.70 16 10448 5233 34941234
Anaemia 22.70 21.70 133 10331 233202 34713265
Neutropenic sepsis 22.43 21.70 24 10440 13743 34932724
Combined immunodeficiency 22.19 21.70 5 10459 68 34946399
Cytopenia 22.19 21.70 23 10441 12700 34933767

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 1242.72 19.95 720 17076 230279 79496313
Encephalopathy 639.43 19.95 308 17488 67089 79659503
Mucosal inflammation 312.41 19.95 200 17596 75380 79651212
Pancytopenia 307.24 19.95 271 17525 165474 79561118
Neutropenia 294.77 19.95 341 17455 287369 79439223
Pyrexia 260.61 19.95 507 17289 678202 79048390
Cystitis haemorrhagic 252.78 19.95 90 17706 9082 79717510
Febrile bone marrow aplasia 165.38 19.95 73 17723 12947 79713645
Aplastic anaemia 157.93 19.95 78 17718 17827 79708765
Thrombocytopenia 143.55 19.95 231 17565 265028 79461564
Venoocclusive liver disease 143.09 19.95 64 17732 11707 79714885
Pseudomonal sepsis 134.63 19.95 51 17745 6123 79720469
Leukopenia 132.32 19.95 146 17650 116367 79610225
Neurotoxicity 126.68 19.95 83 17713 32435 79694157
Haematotoxicity 126.23 19.95 64 17732 15455 79711137
Secondary immunodeficiency 113.38 19.95 38 17758 3196 79723396
Cytokine release syndrome 112.05 19.95 80 17716 35918 79690674
Myelosuppression 88.97 19.95 73 17723 40223 79686369
Toxic encephalopathy 86.73 19.95 45 17751 11395 79715197
Aplasia 83.95 19.95 39 17757 7781 79718811
Arthralgia 83.03 19.95 14 17782 571789 79154803
SARS-CoV-2 test negative 81.02 19.95 24 17772 1347 79725245
Fanconi syndrome 78.57 19.95 28 17768 2828 79723764
Product use in unapproved indication 77.66 19.95 172 17624 250187 79476405
Anal inflammation 75.72 19.95 23 17773 1407 79725185
Bacterial infection 73.99 19.95 59 17737 31221 79695371
Venoocclusive disease 72.47 19.95 30 17766 4543 79722049
Anaemia 68.99 19.95 237 17559 444778 79281814
Bone marrow failure 66.70 19.95 69 17727 51038 79675554
Polyneuropathy 62.40 19.95 48 17748 24103 79702489
Bronchopulmonary aspergillosis 59.12 19.95 45 17751 22249 79704343
Cytomegalovirus viraemia 58.05 19.95 36 17760 12785 79713807
Platelet transfusion 57.10 19.95 21 17775 2321 79724271
Neutrophil count decreased 55.05 19.95 85 17711 93874 79632718
Lymphoid tissue hypoplasia 53.74 19.95 16 17780 914 79725678
Thymus hypoplasia 53.02 19.95 16 17780 957 79725635
Drug ineffective 52.85 19.95 101 17695 1080812 78645780
Acute graft versus host disease 52.35 19.95 31 17765 10136 79716456
Sepsis 49.33 19.95 152 17644 269276 79457316
Mycobacterium chelonae infection 48.93 19.95 19 17777 2437 79724155
T-cell lymphoma refractory 48.75 19.95 9 17787 57 79726535
Off label use 48.63 19.95 357 17439 906858 78819734
Septic shock 48.16 19.95 93 17703 122708 79603884
Cytomegalovirus infection 47.58 19.95 53 17743 42591 79684001
Proctalgia 45.07 19.95 28 17768 9973 79716619
Stomatitis 42.28 19.95 98 17698 146659 79579933
Idiopathic pneumonia syndrome 42.16 19.95 12 17784 584 79726008
Neutropenic sepsis 41.69 19.95 40 17756 27024 79699568
Viral infection 40.52 19.95 49 17747 42967 79683625
Peripheral swelling 40.42 19.95 6 17790 269611 79456981
White blood cell count decreased 38.98 19.95 111 17685 188177 79538415
Agranulocytosis 38.73 19.95 49 17747 44981 79681611
Disseminated aspergillosis 38.65 19.95 13 17783 1105 79725487
Accident 37.98 19.95 24 17772 8807 79717785
Drug hypersensitivity 37.82 19.95 10 17786 298906 79427686
Clostridium difficile colitis 35.80 19.95 40 17756 32243 79694349
Chronic graft versus host disease 35.76 19.95 21 17775 6760 79719832
Fatigue 34.82 19.95 100 17696 929627 78796965
Oesophagitis 33.87 19.95 34 17762 24255 79702337
Fungal infection 33.66 19.95 44 17752 41704 79684888
Dizziness 32.44 19.95 42 17754 526399 79200193
Fall 32.05 19.95 37 17759 487592 79239000
Renal tubular disorder 31.37 19.95 19 17777 6467 79720125
Angiodysplasia 31.06 19.95 11 17785 1091 79725501
Acute graft versus host disease in skin 30.92 19.95 20 17776 7638 79718954
Immune effector cell-associated neurotoxicity syndrome 30.55 19.95 18 17778 5830 79720762
Amniotic fluid index decreased 30.37 19.95 5 17791 14 79726578
Hypokalaemia 29.88 19.95 85 17711 143955 79582637
Peripheral sensory neuropathy 29.57 19.95 24 17772 13009 79713583
Nasopharyngitis 29.37 19.95 10 17786 253871 79472721
Fusarium infection 28.97 19.95 12 17784 1820 79724772
Abdominal discomfort 28.79 19.95 10 17786 250717 79475875
Depersonalisation/derealisation disorder 28.78 19.95 12 17784 1850 79724742
Weight increased 28.68 19.95 13 17783 277373 79449219
Platelet count decreased 28.60 19.95 102 17694 194562 79532030
Cystitis viral 27.30 19.95 9 17787 719 79725873
Haemorrhoids 27.13 19.95 33 17763 29095 79697497
Chronic hepatitis B 27.11 19.95 8 17788 443 79726149
Malassezia infection 26.53 19.95 5 17791 36 79726556
Drug intolerance 26.35 19.95 13 17783 264106 79462486
Hepatitis E 26.29 19.95 13 17783 2973 79723619
Swelling 26.01 19.95 8 17788 216703 79509889
Cytopenia 25.65 19.95 27 17769 20356 79706236
Bacteraemia 25.54 19.95 34 17762 32790 79693802
Leukoencephalopathy 25.53 19.95 18 17778 7911 79718681
Aspergillus infection 25.22 19.95 26 17770 19135 79707457
BK polyomavirus test positive 25.01 19.95 6 17790 148 79726444
Bacterial sepsis 24.99 19.95 18 17778 8180 79718412
Multiple organ dysfunction syndrome 24.97 19.95 71 17725 120175 79606417
Hyperbilirubinaemia 24.85 19.95 29 17767 24489 79702103
Contraindicated product administered 24.80 19.95 3 17793 157535 79569057
Pain in extremity 24.66 19.95 27 17769 364511 79362081
Drug therapeutic incompatibility 24.42 19.95 6 17790 164 79726428
Candida test positive 23.62 19.95 9 17787 1097 79725495
Myocardial infarction 23.58 19.95 6 17790 184123 79542469
Pneumothorax 23.06 19.95 30 17766 28293 79698299
Acute kidney injury 23.05 19.95 196 17600 519208 79207384
Hypoalbuminaemia 22.95 19.95 26 17770 21271 79705321
Graft versus host disease 22.75 19.95 22 17774 15004 79711588
Ejection fraction decreased 22.69 19.95 33 17763 34544 79692048
Staphylococcal bacteraemia 22.59 19.95 20 17776 12198 79714394
Cardiotoxicity 22.56 19.95 20 17776 12219 79714373
Candida sepsis 22.30 19.95 11 17785 2502 79724090
Adenovirus infection 22.28 19.95 17 17779 8430 79718162
Confusional state 22.26 19.95 134 17662 317863 79408729
Tumour lysis syndrome 22.10 19.95 27 17769 23912 79702680
Haematuria 22.08 19.95 48 17748 68788 79657804
Mental status changes 21.83 19.95 47 17749 66912 79659680
Fanconi syndrome acquired 21.58 19.95 11 17785 2683 79723909
Engraftment syndrome 21.50 19.95 9 17787 1400 79725192
Periorbital cellulitis 21.38 19.95 8 17788 927 79725665
Blood phosphorus decreased 21.15 19.95 15 17781 6653 79719939
Amniotic fluid volume decreased 21.12 19.95 6 17790 290 79726302
Rhinovirus infection 20.96 19.95 16 17780 7937 79718655
Hypersensitivity 20.56 19.95 17 17779 262222 79464370
Cardiorenal syndrome 20.46 19.95 9 17787 1580 79725012
Aphasia 20.30 19.95 37 17759 46695 79679897
Rash 20.30 19.95 64 17732 578294 79148298
Bladder telangiectasia 20.15 19.95 3 17793 3 79726589
Posterior reversible encephalopathy syndrome 20.10 19.95 27 17769 26254 79700338

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC R05CB05 RESPIRATORY SYSTEM
COUGH AND COLD PREPARATIONS
EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS
Mucolytics
ATC V03AF01 VARIOUS
ALL OTHER THERAPEUTIC PRODUCTS
ALL OTHER THERAPEUTIC PRODUCTS
Detoxifying agents for antineoplastic treatment
CHEBI has role CHEBI:23354 coenzymes
MeSH PA D020011 Protective Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Testicular Germ Cell Tumor indication
Prevention of Chemotherapy-Induced Hemorrhagic Cystitis indication
Ewing's sarcoma off-label use 76909002 DOID:3369
Burkitt's lymphoma off-label use 118617000
Non-small cell lung cancer off-label use 254637007 DOID:3908
Malignant tumor of head and/or neck off-label use 255056009
Osteosarcoma of bone off-label use 307576001 DOID:3376
Soft or Connective Tissue Sarcoma off-label use
Renal tubular acidosis contraindication 1776003 DOID:14219
Hyperbilirubinemia contraindication 14783006 DOID:2741
Dehydration contraindication 34095006
Fanconi syndrome contraindication 40488004 DOID:1062
Hypokalemia contraindication 43339004
Leukopenia contraindication 84828003 DOID:615
Kidney disease contraindication 90708001 DOID:557
Kidney excision contraindication 108022006
Liver function tests abnormal contraindication 166603001
Disease of liver contraindication 235856003 DOID:409
Impaired wound healing contraindication 271618001
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Bone marrow depression contraindication 307762000
Coma contraindication 371632003
Impaired cognition contraindication 386806002
Breastfeeding (mother) contraindication 413712001
Cancer Chemotherapy Induced Hemorrhagic Cystitis contraindication
Polyneuropathies contraindication
Severe Bone Marrow Depression contraindication
Bone Metastases contraindication
CNS Toxicity contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 0.61 acidic
pKa2 9.77 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4019477 VUID
N0000147597 NUI
D01459 KEGG_DRUG
4019477 VANDF
C0000294 UMLSCUI
CHEBI:62955 CHEBI
CHEMBL1098319 ChEMBL_ID
CHEMBL975 ChEMBL_ID
D015080 MESH_DESCRIPTOR_UI
23662354 PUBCHEM_CID
2813 INN_ID
NR7O1405Q9 UNII
DB09110 DRUGBANK_ID
1546354 RXNORM
41498 MMSL
5057 MMSL
d01411 MMSL
002678 NDDF
108821000 SNOMEDCT_US
386922000 SNOMEDCT_US
COM PDB_CHEM_ID
19767-45-4 SECONDARY_CAS_RN

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
mesna HUMAN PRESCRIPTION DRUG LABEL 1 0143-9260 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 25 sections
MESNEX HUMAN PRESCRIPTION DRUG LABEL 1 0338-1305 INJECTION, SOLUTION 100 mg INTRAVENOUS NDA 27 sections
MESNEX HUMAN PRESCRIPTION DRUG LABEL 1 0338-1305 INJECTION, SOLUTION 100 mg INTRAVENOUS NDA 27 sections
MESNEX HUMAN PRESCRIPTION DRUG LABEL 1 0338-1307 INJECTION, SOLUTION 1 mg INTRAVENOUS NDA 24 sections
MESNEX HUMAN PRESCRIPTION DRUG LABEL 1 0338-1307 INJECTION, SOLUTION 100 mg INTRAVENOUS NDA 24 sections
MESNEX HUMAN PRESCRIPTION DRUG LABEL 1 0338-1307 INJECTION, SOLUTION 100 mg INTRAVENOUS NDA 24 sections
MESNA HUMAN PRESCRIPTION DRUG LABEL 1 10019-951 INJECTION, SOLUTION 100 mg INTRAVENOUS NDA 26 sections
MESNA HUMAN PRESCRIPTION DRUG LABEL 1 10019-951 INJECTION, SOLUTION 100 mg INTRAVENOUS NDA 26 sections
MESNA HUMAN PRESCRIPTION DRUG LABEL 1 10019-953 INJECTION, SOLUTION 100 mg INTRAVENOUS NDA 26 sections
MESNA HUMAN PRESCRIPTION DRUG LABEL 1 10019-953 INJECTION, SOLUTION 100 mg INTRAVENOUS NDA 26 sections
Mesna HUMAN PRESCRIPTION DRUG LABEL 1 25021-201 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 26 sections
mesna HUMAN PRESCRIPTION DRUG LABEL 1 62778-304 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 2 sections
Mesna Human Prescription Drug Label 1 63323-733 INJECTION, SOLUTION 100 mg INTRAVENOUS ANDA 27 sections
MESNEX HUMAN PRESCRIPTION DRUG LABEL 1 67108-3565 TABLET, FILM COATED 400 mg ORAL NDA 26 sections
MESNEX HUMAN PRESCRIPTION DRUG LABEL 1 67108-3565 TABLET, FILM COATED 400 mg ORAL NDA 26 sections
Mesna Human Prescription Drug Label 1 68083-161 SOLUTION 100 mg INTRAVENOUS ANDA 26 sections
Mesna Human Prescription Drug Label 1 68083-161 SOLUTION 100 mg INTRAVENOUS ANDA 26 sections